<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678426-A1" country="EP" doc-number="2678426" kind="A1" date="20140101" family-id="46720040" file-reference-id="252637" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551641" ucid="EP-2678426-A1"><document-id><country>EP</country><doc-number>2678426</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-11859343-A" is-representative="NO"><document-id mxw-id="PAPP154825564" load-source="docdb" format="epo"><country>EP</country><doc-number>11859343</doc-number><kind>A</kind><date>20110225</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220438442" load-source="docdb" format="original"><country>EP</country><doc-number>11859343.3</doc-number><date>20110225</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140453046" ucid="CA-2011000208-W" linkage-type="A" load-source="docdb"><document-id format="epo"><country>CA</country><doc-number>2011000208</doc-number><kind>W</kind><date>20110225</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-2091440434" load-source="docdb">C07K  14/37        20060101ALI20150213BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2091441451" load-source="docdb">A01N  63/04        20060101ALI20150213BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2091444912" load-source="docdb">C12N  15/82        20060101ALI20150213BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2091446185" load-source="docdb">C12N   5/10        20060101AFI20150213BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2091446303" load-source="docdb">A01P   3/00        20060101ALI20150213BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2091446823" load-source="docdb">A01N  63/02        20060101ALI20150213BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2091451611" load-source="docdb">C12N  15/31        20060101ALI20150213BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988120544" load-source="docdb" scheme="CPC">A01N  63/04        20130101 LI20130614BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988123224" load-source="docdb" scheme="CPC">C07K  14/37        20130101 FI20130906BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988125505" load-source="docdb" scheme="CPC">C12N  15/8282      20130101 LI20130906BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132187407" lang="DE" load-source="patent-office">PROTEINE ZUR BIOLOGISCHEN KONTROLLE VON PFLANZENPATHOGENEN PILZEN</invention-title><invention-title mxw-id="PT132187408" lang="EN" load-source="patent-office">PROTEINS FOR BIOCONTROL OF PLANT PATHOGENIC FUNGI</invention-title><invention-title mxw-id="PT132187409" lang="FR" load-source="patent-office">PROTÉINES POUR LA LUTTE BIOLOGIQUE CONTRE DES CHAMPIGNONS PATHOGÈNES DE PLANTES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918137862" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV SASKATCHEWAN</last-name><address><country>CA</country></address></addressbook></applicant><applicant mxw-id="PPAR918137420" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>UNIVERSITY OF SASKATCHEWAN</last-name></addressbook></applicant><applicant mxw-id="PPAR918980476" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>University Of Saskatchewan</last-name><iid>101333915</iid><address><street>Office of Vice-President of Research Industry Liaison Office Box 5000 RPO University</street><city>Saskatoon, Saskatchewan S7N 1K2</city><country>CA</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918154922" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>VUJANOVIC VLADIMIR</last-name><address><country>CA</country></address></addressbook></inventor><inventor mxw-id="PPAR918136032" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>VUJANOVIC, VLADIMIR</last-name></addressbook></inventor><inventor mxw-id="PPAR918987835" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>VUJANOVIC, VLADIMIR</last-name><address><street>211-301 Tait Place</street><city>Saskatoon Saskatchewan S7H 5L5</city><country>CA</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918990114" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Kelly, Donal Morgan</last-name><suffix>et al</suffix><iid>101404231</iid><address><street>FRKelly 27 Clyde Road</street><city>Dublin 4</city><country>IE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="CA-2011000208-W"><document-id><country>CA</country><doc-number>2011000208</doc-number><kind>W</kind><date>20110225</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012113051-A1"><document-id><country>WO</country><doc-number>2012113051</doc-number><kind>A1</kind><date>20120830</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548938374" load-source="docdb">AL</country><country mxw-id="DS548945362" load-source="docdb">AT</country><country mxw-id="DS548868894" load-source="docdb">BE</country><country mxw-id="DS548839674" load-source="docdb">BG</country><country mxw-id="DS548933900" load-source="docdb">CH</country><country mxw-id="DS548868895" load-source="docdb">CY</country><country mxw-id="DS548945363" load-source="docdb">CZ</country><country mxw-id="DS548938375" load-source="docdb">DE</country><country mxw-id="DS548868896" load-source="docdb">DK</country><country mxw-id="DS548868897" load-source="docdb">EE</country><country mxw-id="DS548937395" load-source="docdb">ES</country><country mxw-id="DS548839675" load-source="docdb">FI</country><country mxw-id="DS548933901" load-source="docdb">FR</country><country mxw-id="DS548938376" load-source="docdb">GB</country><country mxw-id="DS548868898" load-source="docdb">GR</country><country mxw-id="DS548938377" load-source="docdb">HR</country><country mxw-id="DS548945364" load-source="docdb">HU</country><country mxw-id="DS548933902" load-source="docdb">IE</country><country mxw-id="DS548868899" load-source="docdb">IS</country><country mxw-id="DS548839676" load-source="docdb">IT</country><country mxw-id="DS548868900" load-source="docdb">LI</country><country mxw-id="DS548839677" load-source="docdb">LT</country><country mxw-id="DS548922096" load-source="docdb">LU</country><country mxw-id="DS548839678" load-source="docdb">LV</country><country mxw-id="DS548839679" load-source="docdb">MC</country><country mxw-id="DS548922097" load-source="docdb">MK</country><country mxw-id="DS548922182" load-source="docdb">MT</country><country mxw-id="DS548922183" load-source="docdb">NL</country><country mxw-id="DS548933903" load-source="docdb">NO</country><country mxw-id="DS548922184" load-source="docdb">PL</country><country mxw-id="DS548937396" load-source="docdb">PT</country><country mxw-id="DS548817871" load-source="docdb">RO</country><country mxw-id="DS548937397" load-source="docdb">RS</country><country mxw-id="DS548922185" load-source="docdb">SE</country><country mxw-id="DS548938390" load-source="docdb">SI</country><country mxw-id="DS548933904" load-source="docdb">SK</country><country mxw-id="DS548933905" load-source="docdb">SM</country><country mxw-id="DS548868901" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99627099" ref-ucid="WO-2012113051-A1" lang="EN" load-source="patent-office"><p num="0000">A composition for controlling disease symptoms caused by plant pathogenic fungi exemplified by Fusarium spp., <i>Sclerotinia spp</i>.,<i> Rhizoctonia spp</i>., <i>Pithium spp</i>., and the like. The composition is provided with a polypeptide molecule comprising an amino acid sequence sharing at least 80% sequence identity with SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, or SEQ ID NO: 7. The composition may be one of a seed treatment, a plant treatment or a soil treatment. A transformed plant cell expressing a polypeptide molecule comprising an amino acid sequence sharing at least 80% sequence identity with SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7 whereby said plant cell is resistant to infection by plant pathogenic fungi. A transformed microbial cell expressing a polypeptide molecule comprising an amino acid sequence sharing at least 80% sequence identity with SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.</p></abstract><abstract mxw-id="PA99825606" ref-ucid="WO-2012113051-A1" lang="EN" source="national office" load-source="docdb"><p>A composition for controlling disease symptoms caused by plant pathogenic fungi exemplified by Fusarium spp., Sclerotinia spp., Rhizoctonia spp., Pithium spp., and the like. The composition is provided with a polypeptide molecule comprising an amino acid sequence sharing at least 80% sequence identity with SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, or SEQ ID NO: 7. The composition may be one of a seed treatment, a plant treatment or a soil treatment. A transformed plant cell expressing a polypeptide molecule comprising an amino acid sequence sharing at least 80% sequence identity with SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7 whereby said plant cell is resistant to infection by plant pathogenic fungi. A transformed microbial cell expressing a polypeptide molecule comprising an amino acid sequence sharing at least 80% sequence identity with SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.</p></abstract><abstract mxw-id="PA99627100" ref-ucid="WO-2012113051-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne une composition permettant de contrôler les symptômes d'une maladie provoqués par des champignons pathogènes de plantes, comme par exemple <i>Fusarium spp</i>., <i>Sclerotinia spp</i>.,<i> Rhizoctonia spp</i>., <i>Pithium spp</i>., et similaires. La composition contient une molécule polypeptidique comprenant une séquence d'acides aminés partageant au moins 80 % d'identité de séquence avec SEQ ID n° 4, SEQ ID n° 5, SEQ ID n° 6, ou SEQ ID n° 7. La composition peut être utilisée pour un traitement de semences, un traitement de plantes ou un traitement de sol. L'invention concerne également une cellule végétale transformée exprimant une molécule polypeptidique comprenant une séquence d'acides aminés partageant au moins 80 % d'identité de séquence avec SEQ ID n° 4, SEQ ID n° 5, SEQ ID n° 6, ou SEQ ID n° 7, ladite cellule végétale étant résistante à l'infection par les champignons pathogènes de plantes. L'invention concerne également une cellule microbienne transformée exprimant une molécule polypeptidique comprenant une séquence d'acides aminés partageant au moins 80 % d'identité de séquence avec SEQ ID n° 4, SEQ ID n° 5, SEQ ID n° 6, ou SEQ ID n° 7.</p></abstract><abstract mxw-id="PA99825607" ref-ucid="WO-2012113051-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne une composition permettant de contrôler les symptômes d'une maladie provoqués par des champignons pathogènes de plantes, comme par exemple Fusarium spp., Sclerotinia spp., Rhizoctonia spp., Pithium spp., et similaires. La composition contient une molécule polypeptidique comprenant une séquence d'acides aminés partageant au moins 80 % d'identité de séquence avec SEQ ID n° 4, SEQ ID n° 5, SEQ ID n° 6, ou SEQ ID n° 7. La composition peut être utilisée pour un traitement de semences, un traitement de plantes ou un traitement de sol. L'invention concerne également une cellule végétale transformée exprimant une molécule polypeptidique comprenant une séquence d'acides aminés partageant au moins 80 % d'identité de séquence avec SEQ ID n° 4, SEQ ID n° 5, SEQ ID n° 6, ou SEQ ID n° 7, ladite cellule végétale étant résistante à l'infection par les champignons pathogènes de plantes. L'invention concerne également une cellule microbienne transformée exprimant une molécule polypeptidique comprenant une séquence d'acides aminés partageant au moins 80 % d'identité de séquence avec SEQ ID n° 4, SEQ ID n° 5, SEQ ID n° 6, ou SEQ ID n° 7.</p></abstract><description mxw-id="PDES50931775" ref-ucid="WO-2012113051-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> PROTEINS FOR BIOCONTROL OF PLANT PATHOGENIC FUNGI </p><p id="p0002" num="0002">FIELD OF THE INVENTION </p><p id="p0003" num="0003"> The present invention relates to novel biocontrol agents, related compositions effective for controlling fungal plant pathogens and uses thereof. In particular, the present invention relates to novel proteins having mycostatic and/or mycocidal effects on plant pathogenic fungi. The present invention further relates to biocontrol agents comprising the proteins as well as uses, methods, compositions, involving the same. </p><p id="p0004" num="0004">BACKGROUND TO THE INVENTION </p><p id="p0005" num="0005"> Fusarium is a filamentous fungus widely distributed on plants and in the soil. Certain</p><p id="p0006" num="0006">Fusarium species are plant pathogens. For example, Fusarium oxysporum causes Fusarium wilt disease in more than a hundred species of plants. It does so by colonizing the plant xylem which can result in blockage and breakdown. When this occurs symptoms such as leaf wilting and yellowing appear in the plant, eventually leading to the plant's death. This condition was the primary cause of the decline and disappearance of the Gros Michel banana cultivar from markets around the world. Recently a new strain has begun attacking plants of the dominant Cavendish cultivar leading to fears that, in the absence of a solution, this cultivar will also disappear from world markets. </p><p id="p0007" num="0007">Fusarium root rot is a major cause of seedling mortality in forest nurseries and also causes reduced survival after outplanting during the first growing season. The disease is caused by several Fusarium species and is common in many parts of the world. The disease is a particular problem in Western Canada and the United States and also in the North Central and Southern States. In addition, Pine pitch canker - caused by the fungus Fusarium circinatum - is a serious disease of pine trees and a threat to the forest industry particularly in the United States and New Zealand. Radiata or Monterey pine is highly susceptible to the disease with mortality rates in mature trees reaching 80% in some areas of California. </p><p id="p0008" num="0008">Fusarium Head Blight (FHB), also known as 'ear blight' or 'scab', is a disease of wheat, barley, oats and other small cereal grains caused by Fusarium. Corn and maize can be affected by a similar condition known as 'ear rot'. The aforementioned condition can reduce the yield and grade of the crop, and can potentially contaminate the grain with mycotoxins. It is estimated that FHB costs the cereal industry almost $5 billion annually. In recent years, 
<!-- EPO <DP n="3"/>-->
 FHB has proved a significant and growing problem for the commercially important wheat and barley crops in Western Canada. In the past, Fusarium oxysporum and Fusarium avenaceum have been identified as the two species primarily associated with FHB in Canada where yields in some affected fields have been reduced by 30% or more. FHB and ear rot harvested grain is often contaminated with mycotoxins such as deoxinivalenol (DON) trichothecenes which are associated with feed refusal, general digestive disorders, diarrhea, and hemorrhages. The emergence of the toxigenic 3-acetyldeoxynivalenol (3-ADON) Fusarium graminearum population in North America is a fairly recent phenomenon. It is replacing the 15-ADON chemotype. Moreover, the mycotoxin profiles of F. culmorum - similar to F. graminearum under both laboratory and field conditions-represents an additional threat for corn, maize and wheat production worldwide. Currently, there are no effective control measures for FHB and associated mycotoxins. Additionally, there are also no resistant varieties of corn, wheat, barley, oats, or other small grain cereals. Fungicides can be effective but they only temporarily suppress the disease. In addition to being a common plant pathogen, Fusarium spp. can opportunistically infect animals and can be the causative agents of superficial and/or systemic infections in humans. Fusaria are one of the most drug-resistant fungi making Fusaria infections difficult to treat. Invasive infections can prove fatal. </p><p id="p0009" num="0009">Sclerotinia stem rot is caused by the pathogen Sclerotinia sclerotiorum. S. sclerotiorum has a wide host range and is known to infect numerous species of plants (canola, sunflower, soybean, flax, etc.). Disease outbreaks can be particularly severe under conditions of zero crop rotation or if rotations include several susceptible plant species. Yield losses can reach 20% when infections occur early in the flowering period. Another wide-spread fungal plant pathogen is Rhizoctonia which causes "damping off' or "wire-stem" disease symptoms in crop plants. Infection can occur at any time during the growing season, but the seedling stage is most susceptible. Incidence and severity of disease at all growth stages are influenced by weather, soil conditions and inoculum levels. Seedling infection is favoured by cool weather. As well, incidences of wirestem disease are most severe in spring and fall when soils are wet and cool. Root rots generally occur during periods of warm, wet weather and may affect the plant at any stage of development. Seedlings affected by damping-off fail to emerge or if they do, they quickly decline, topple over and die. In older seedlings, there is purpling on the lower leaves and the lower stem becomes constricted and dark-brown near 
<!-- EPO <DP n="4"/>-->
 the soil surface. Other symptoms may include seed decay, rotting roots and cankers on lower petioles. Pythium ultimum is a ubiquitous soilborne pathogen widely distributed throughout the world, that causes damping-off and root rot on plants. P. ultimum has a wide range of hosts including many important agronomic crops and turf grasses. SUMMARY OF THE INVENTION </p><p id="p0010" num="0010"> The present invention relates to novel proteins that control fungal pathogens and/or disease symptoms caused by plant pathogenic fungi exemplified by Fusarium spp., Sclerotinia spp., Rhizoctonia spp., Pithium spp., and the like. Furthermore, these novel proteins also have anti-mycotoxin effects on toxins produced by plant pathogenic fungi exemplified by Fusarium spp., Sclerotinia spp., Rhizoctonia spp., Pithium spp., and the like. </p><p id="p0011" num="0011">Some exemplary embodiments of the present invention relate to novel intracellular proteins produced by Sphaerodes mycoparasitica that are useful for controlling and/or preventing germination of plant pathogenic fungal spores, and/or controlling proliferation of plant pathogenic fungal mycelia, and/or preventing plant pathogenic fungi from infecting plant cells, or any combination thereof. </p><p id="p0012" num="0012">Some exemplary embodiments of the present invention relate to novel extracellular proteins produced by S. mycoparasitica that are useful for controlling and/or preventing germination of plant pathogenic fungal spores, and/or controlling proliferation of plant pathogenic fungal mycelia, and/or preventing plant pathogenic fungi from infecting plant cells, or any combination thereof. </p><p id="p0013" num="0013">One aspect of the present invention pertains to a novel extracellular protein produced by S. mycoparasitica that comprises SEQ ID NO:4 and has a molecular weight of about 79 kDa. </p><p id="p0014" num="0014">One aspect of the present invention pertains to a novel extracellular protein produced by S. mycoparasitica that comprises SEQ ID NO:5 and has a molecular weight of about 50 kDa. </p><p id="p0015" num="0015">One aspect of the present invention pertains to a novel extracellular protein produced by S. mycoparasitica that comprises SEQ ID NO:6 and has a molecular weight of about 36 kDa. 
<!-- EPO <DP n="5"/>-->
 One aspect of the present invention pertains to a novel extracellular protein produced by S. mycoparasitica that comprises SEQ ID NO: 7 and has a molecular weight of about 13 kDa. </p><p id="p0016" num="0016">Some exemplary embodiments of the present invention pertain to compositions comprising one or more of the novel extracellular proteins. The compositions may be seed treatment compositions, or they may be plant treatment compositions, or they may be soil treatment compositions. </p><p id="p0017" num="0017">Some exemplary embodiments of the present invention pertain to microbial cells transformed to produce one or more of the novel intracellular proteins and novel extracellular proteins. The transformed microbial cells can be used to control disease symptoms caused by plant pathogenic fungi exemplified by Fusarium spp., Sclerotinia spp., Rhizoctonia spp., Pithium spp., and the like. The transformed microbial cells can be used as seed treatments and/or plant treatments and/or soil treatments, or any combination thereof. Alternatively, the transformed microbial cells can be used to produce the novel proteins. The proteins can be harvested and used to prepare the compositions of the present invention. </p><p id="p0018" num="0018">Some exemplary embodiments of the present invention pertain to transformed plant cells that over-express one or more of the novel proteins. Such transformed plant cells can be comprised in plant propagules exemplified by seeds, somatic embryos, organogenic tissues and the like, that can be cultured into whole plants. Whole plants comprising the transformed plant cells are resistant to, or at least tolerant of disease symptoms caused by plant pathogenic fungi exemplified by Fusarium spp., Sclerotinia spp., Rhizoctonia spp., Pithium spp., and the like. </p><p id="p0019" num="0019">BRIEF DESCRIPTION OF THE DRAWINGS </p><p id="p0020" num="0020"> Exemplary embodiments of the present invention are described in conjunction with reference to the following drawings, in which: </p><p id="p0021" num="0021">Figs. l(a)A and l(a)B are micrographs of a disc diffusion assay showing the inhibitory effects of exemplary proteins of the present invention on mycelial growth of Fusarium oxysporum (1(a) A) and F. graminearum (l(a)B), and Fig. 1(b) is a chart showing the % inhibition of mycelial growth of F. oxysporum (A) and F. graminearum (B) by the exemplary proteins after 3 days and 4 days of growth; 
<!-- EPO <DP n="6"/>-->
 Fig. 2 is a micrograph of 10% native-PAGE separation of intracellular proteins produced by Sphaerodes mycoparasitica into two bands; </p><p id="p0022" num="0022">Fig. 3 is a micrograph of 12% SDS-PAGE separation of S. mycoparasitica intracellular proteins eluted from the upper band and lower band indicated on the 10% native- PAGE gel shown in Fig. 2; </p><p id="p0023" num="0023">Fig. 4 is a micrograph of 10% native-PAGE separation of extracellular proteins produced by S. mycoparasitica into four bands; </p><p id="p0024" num="0024">Fig. 5 is a micrograph of 12% SDS-PAGE separation of S. mycoparasitica extracellular proteins eluted from the four bands of the 10% native-PAGE gel shown in Fig. 4; </p><p id="p0025" num="0025">Fig. 6 is a chromatogram showing FLPC separation of the four bands of extracellular proteins produced by S. mycoparasitica; </p><p id="p0026" num="0026">Fig. 7(a) is a micrograph of mycelial growth of F. oxysporum in the control treatment; 7(b) is a micrograph of mycelial growth of F. oxysporum in the control treatment plus buffer; 7(c) is a micrograph of the inhibitory effects of the 50 kDa intracellular protein on mycelial growth of F. oxysporum; and 7(d) is a micrograph of the inhibitory effects of the 79 kDa intracellular protein on mycelial growth of F. oxysporum; </p><p id="p0027" num="0027">Fig. 8(a) is a micrograph of mycelial growth of F. graminearum in the control treatment; 8(b) is a micrograph of mycelial growth of F. graminearum in the control treatment plus buffer; 8(c) is a micrograph of the inhibitory effects of the 50 kDa intracellular protein on mycelial growth of F. graminearum; and 8(d) is a micrograph of the inhibitory effects of the 79 kDa intracellular protein on mycelial growth of F. graminearum; </p><p id="p0028" num="0028">Fig. 9(a) is a micrograph showing the inhibition of mycelial outgrowth of F. oxysporum by the 79 kDa extracellular protein (ECl) compared to the control treatment (c), and 9(b) is a micrograph showing the inhibition of mycelial outgrowth of F. oxysporum by the 50 kDa extracellular protein (EC2) and the 36 kDa extracellular protein (EC3); </p><p id="p0029" num="0029">Fig 10(a) is a micrograph showing the inhibition of mycelial outgrowth of F. graminearum by the 79 kDa extracellular protein (ECl) compared to the control treatment (c), and 10(b) is a micrograph showing the inhibition of mycelial outgrowth of F. 
<!-- EPO <DP n="7"/>-->
 graminearum by the 50 kDa extracellular protein (EC2) and the 36 kDa extracellular protein (EC3); </p><p id="p0030" num="0030">Fig. 11(a) is a micrograph showing the inhibition of mycelial outgrowth of F. graminearum by the 13 kDa extracellular protein (EC4) compared to the control treatment (c), and 1 1(b) is a micrograph showing the inhibition of mycelial outgrowth of F. oxysporum by the 13 kDa extracellular protein (EC4) compared to the control treatment (c); </p><p id="p0031" num="0031">Figs. 12(a) and 12(b) are charts showing the effects of S. mycoparasitica extracellular protein fractions ECl, EC2, EC3, and EC4 on germination of F. oxysporum spores 12(a) and F. graminearum spores 12(b); Fig. 13 is a chart showing the effects of S. mycoparasitica extracellular protein fractions ECl, EC2, EC3, and EC4 on inhibition of colony growth and development of F. oxysporum and F. graminearum; </p><p id="p0032" num="0032">Figs. 14A(c), 14A(a), 14A(b) are micrographs showing germination of control F. oxysporum spores (c), the inhibitory effects of the 50 kDa protein (a), and the inhibitory effects of the 13 kDa protein on germination of F. oxysporum spores, and Figs. 14B(c), 14B(a), 14B(b) are micrographs showing germination of control F. graminearum spores (c), the inhibitory effects of the 50 kDa protein (a), and the inhibitory effects of the 13 kDa protein on germination of F. graminearum spores; </p><p id="p0033" num="0033">Figs. 15(a) and 15(b) are micrographs showing the effects of crystal-forming extracellular proteins ECl and EC3 on mycelial growth of F. avenaceum (15(b)) in comparison to the control (15(a)); </p><p id="p0034" num="0034">Figs. 16(a) and 16(c) are micrographs showing the effects crystal-forming extracellular proteins ECl and EC3 on the colonization of germinating wheat seeds and mycelial growth of F. graminearum (16(b)) in comparison to the control (16(a)), while 16(c) is a confocal laser scanning microscopy micrograph showing numerous lysed F. graminearum hyphal elements (see arrows) from the surface of the wheat seedlings treated with the extracellular proteins. "K+" indicates that the medium contained the ECl and EC3 extracellular proteins. "K-" indicates that the ECl and EC3 extracellular proteins were absent from the medium. "K-crystal" identifies the location of an extracellular protein molecule(s); 
<!-- EPO <DP n="8"/>-->
 Figs. 17(a) and 17(b) are micrographs showing the effects of the crystal-forming extracellular proteins ECl and EC3 on mycelial growth of F. graminearum (17(b)) in comparison to the control (17(a)); </p><p id="p0035" num="0035">Fig. 18(a) is a scanning electron microscopy micrograph showing the presence of protein crystals and lysed fungal hyphae from the crystal-protein-treated F. graminearum from Fig. 17(b), 18(b) is a confocal laser scanning microscopy micrograph showing the presence of protein crystals among the hyphae of the crystal-protein-treated F. graminearum from Fig. 17(b), and 18(c) is a chemical force microscopy micrograph showing the presence of protein crystals and numerous broken hyphal elements and apoptotic-lysed cells (arrows) from the crystal -protein-treated F. graminearum from Fig. 17(b). "K crystal: indentifies the location of an extracellular protein molecule(s)"; </p><p id="p0036" num="0036">Fig. 19 is a chart showing MALDI-TOF-MS separation of the amino acids comprising the 79 kDA ECl protein; </p><p id="p0037" num="0037">Fig. 20 is a chart showing MALDI-TOF-MS separation of the amino acids comprising the 50kDa EC2 protein; </p><p id="p0038" num="0038">Fig. 21 is a chart showing MALDI-TOF-MS separation of the amino acids comprising the 36 kDa EC3 protein; </p><p id="p0039" num="0039">Fig. 22 is a chart showing MALDI-TOF-MS separation of the amino acids comprising the 13 kDa EC3 protein; Figs. 23(a)-23(f) are micrographs of: (23(a)) a control untreated culture of Sclerotinia sclerotiorum on PDA, (23(b)) a S. sclerotiorum culture grown on PDA amended with extracellular proteins ECl plus EC3, (23(c)) a control untreated culture of Rhizoctonia solani, (23(d)) a R. solani culture grown on PDA amended with extracellular proteins ECl plus EC3, (23(e)) a control untreated culture of Pythium ultimum, and (23(f)) a P. ultimum culture grown on PDA amended with extracellular proteins ECl plus EC3; and </p><p id="p0040" num="0040">Fig. 24 is a chart showing the inhibitory effects of the the crystal-forming extracellular proteins ECl and EC3 on mycelial growth of Sclerotinia sclerotiorum, Rhizoctonia solani, and Pithium ultimum. 
<!-- EPO <DP n="9"/>-->
 DETAILED DESCRIPTION OF THE INVENTION </p><p id="p0041" num="0041"> Sphaerodes mycoparasitica (Ascomycetes, Melanosporales) is a mycoparasite that has been isolated from isolates of Fusarium avenaceum, Fusarium graminearum and Fusarium oxysporum originating from wheat or asparagus fields. The species is characterized by a unique combination of ascospore size, shape (fusiform and triangular) and wall ornamentation (reticulate and smooth). Also, conidia are produced from simple phialides on the surface of ascoma peridial wall, on ascoma surrounding hyphae, and on irregularly branched conidiophores arising from hyphae. S. mycoparasitica has a phialidic anamorph and produces simple phialides on the surface of ascoma peridial wall or scattered irregularly on ascoma surrounding the hyphae, and on conidiosphores. S. mycoparasitica forms hook-like structures parasitizing living hyphae of Fusarium. </p><p id="p0042" num="0042">Sample cultures of Sphaerodes mycoparasitica have been deposited with the International Depositary Authority of Canada Collection (1015 Arlington Street, Winnipeg, Canada, R3E 3R2) under the accession number IDAC301008-01. Sample cultures of Sphaerodes mycoparasitica biotrophically parasitizing Fusarium avenaceum (teleomorph: Giberella avenacea) have been deposited with the International Depositary Authority of Canada Collection under the accession number IDAC301008-02, and is referred to herein as "SM-Bst". Sample cultures of Sphaerodes mycoparasitica biotrophically parasitizing Fusarium graminearum (telemorph: Giberella zeae) have been deposited with the International Depositary Authority of Canada Collection under the accession number IDAC301008-03 , and is referred to herein as "SM-Gst". </p><p id="p0043" num="0043">The 1266bp DNA sequence from the large subunit ribosomal RNA gene (LSU) of S. mycoparasitica is given in SEQ ID NO: 1. </p><p id="p0044" num="0044">SEQ ID NO: 1. </p><p id="p0045" num="0045"> 1 atagggagaa gaagcactgc gattgcccta gtaacggcga gtgaagcggc agcagcccag </p><p id="p0046" num="0046"> 61 atttggaatc tggtcctttt ggggcccgag ttgtaatctg cagaggaagc gtctggtgcg </p><p id="p0047" num="0047"> 121 gtgccggcct agttccctgg aacgggacgc cgtagagggt gacagccccg tacggtcggc </p><p id="p0048" num="0048"> 181 caccaaacct gtgtgtcgct ccttcgaaga gtcgcgtagt ttgggaatgc tgcgtaaagt </p><p id="p0049" num="0049"> 241 gggaggtatg ctcctcctaa ggctaaatac cggccagaga ccgatagcgc acaagtagag </p><p id="p0050" num="0050"> 301 tgatcgaaag atgaaaagca ccttgaaaat ggggttaaaa agtacgtgaa attgccaaag </p><p id="p0051" num="0051"> 361 gggaagcgct cgtggccaga ctcgtgcctt atggatcatc cggctatttc gccggtgcac </p><p id="p0052" num="0052"> 421 tccattaggc tcgggccagc gtcggtcggc gccggtacta aaagacagcg cgaacgtggc 
<!-- EPO <DP n="10"/>-->
 481 tctcttcggg gagtgttata gcgcgctgtg taatgtgctg gcgccgtccg aggaccgcgc</p><p id="p0053" num="0053">541 atttatgcaa ggacgctggc gtaatggcca ctagcgaccc gtcttgaaac acggaccaag </p><p id="p0054" num="0054"> 601 gagtcgccca gagacgcgag tgtgcgggtg acaaacccct gcgcgaagtg aaagcgaacg </p><p id="p0055" num="0055"> 661 ctggtgggaa ccctcacggg tgcaccaccg accgatcctg atgtcttcgg atggatttga </p><p id="p0056" num="0056"> 721 gtatgagcgt ttctggtcgg acccgaaaga gggtgaacta tgcttgggta gggtgaagcc </p><p id="p0057" num="0057"> 781 agaggaaact ctggtggagg ccccgtttgg gttctgacgt gcaaatcgat ccataaacct </p><p id="p0058" num="0058"> 841 gggcatagcg gcgaaagact aatcgaacct tctagtagct ggttcgcatt ctctctctcg </p><p id="p0059" num="0059"> 901 cacgagagag agaaaacctc tgtgatatca cgattatcag tgaaaaccac accgagaccc </p><p id="p0060" num="0060"> 961 aacggagttc ttctggattt cctcatgctt caattaccac gcctagtgga cctacctgga </p><p id="p0061" num="0061"> 1021 gcgctacaat aaagtcatac gaaaatctcg aagatcgggg tgacggtgag ggatcctaag </p><p id="p0062" num="0062"> 1081 gttctctcgt tgagtgcgtt ggacgggcat ggccgtcagc gatctggggc gaccgttgcc </p><p id="p0063" num="0063"> 1141 ggatcataag ggctttagtg cttaggctat tggtattgag gggtctgaag acggtaatct </p><p id="p0064" num="0064"> 1201 gaaaccaaag gctttattct aaacccgcgc agcatgggcg tagtaggaag agacagcgaa </p><p id="p0065" num="0065"> 1261 gtctag </p><p id="p0066" num="0066">The 1233bp DNA sequence from the small subunit ribosomal RNA gene (SSU) of S. mycoparasitica is given in SEQ ID NO: 2. </p><p id="p0067" num="0067">SEQ ID NO: 2 </p><p id="p0068" num="0068"> 1 agtgcggcat gttgtagcct aagcaattat acagcgaaac tgcgaatggc tcattatata </p><p id="p0069" num="0069"> 61 agttatcgtt tatttgatag tgccttacta cttggataac cgtggtaatt ctagagctaa </p><p id="p0070" num="0070"> 121 tacatgctga aagccccgac ttacggaggg gcgtatttat tagattaaaa accaatgccc </p><p id="p0071" num="0071"> 181 ttcggggctc tttggtgatt catgataact tctcgaatcg cacggccttg cgccggcgat </p><p id="p0072" num="0072"> 241 ggttcattca aatttcttcc ctatcaactt tcgatgtttg ggtagtggcc aaacatggtg </p><p id="p0073" num="0073"> 301 gcaacgggta acggagggtt agggctcgac cccggagaag gagcctgaga aacggctcct </p><p id="p0074" num="0074"> 361 acatccaagg aaggcagcag gcgcgcaaat tacccaatct caactcgagg aggtagtgac </p><p id="p0075" num="0075"> 421 aataaatacc gatgcagggc tctttagggt cttgcaattg gaatgagtac aatttaaatc </p><p id="p0076" num="0076"> 481 ccttaacgag gaacaattgg agggcaagtc tggtgccagc agccgcggta actccagctc </p><p id="p0077" num="0077"> 541 caatagcgta tattaaagtt gttgtggtta aaaagctcgt agttgaacct tgggcctggc </p><p id="p0078" num="0078"> 601 cggctggtcc gcctaacagc gtgcactggt gcggccgggt cttcccaccg cggagccgca </p><p id="p0079" num="0079"> 661 tgtccttcac tgggcgtgtc ggggaagcgg tacttttact gtgaaaaaat tagagtgctc </p><p id="p0080" num="0080"> 721 taagcaggcc tatgctcgaa tacattagca tggaataata gaataggaca gtcgttctat </p><p id="p0081" num="0081"> 781 tttgttggtt tctaggacgt ctgtaatgat taacagaaac aatcgggggc gtcagtattg 
<!-- EPO <DP n="11"/>-->
 841 catcgtcaga ggtgaaattc ttagatcgat gcaagactaa ctactgcgaa agcattcgcc</p><p id="p0082" num="0082">901 aagggtgttt tcattaatca ggaacgaaag ttaggggatc gaagacgatc agataccgtc </p><p id="p0083" num="0083"> 961 gtagtcttaa ccataaacta tgccgactag ggatcgggcg gtgtaatttt gacccgctcg </p><p id="p0084" num="0084"> 1021 gcacttacga gaaatcttaa gtgcttgggc tccaggggag tatggtcgca aggctgaaac </p><p id="p0085" num="0085"> 1081 ttaaagaaat gacgaagggc accaccaagg gtgaacctgc ggcctagttg actcacacgg </p><p id="p0086" num="0086"> 1 141 gaaactcacg aggtaggaat atgtagatga cggatggagc cttcagaata catatgggca </p><p id="p0087" num="0087"> 1201 tgcgctctta ataccggtat tgaaaatggg cag </p><p id="p0088" num="0088">Novel proteins produced by Sphaerodes mycoparasitica as disclosed herein are useful as anti-fungal agents. These novel proteins may be used to treat, ameliorate, or otherwise control infections of Fusarium fungi. These novel proteins produced by S. mycoparasitica are particularly useful for treating, ameliorating or otherwise controlling infections of Fusarium avenaceum, Fusarium graminearum, and/or Fusarium oxysporum and improving plant health or growth. </p><p id="p0089" num="0089">The novel S. mycoparasitica proteins disclosed herein may be used as prophylactic agents to diminish the chances of fungal infections, particularly Fusarium infections, from occurring. </p><p id="p0090" num="0090">The novel S. mycoparasitica proteins disclosed herein may be used for treating plants affected by Fusarium Wilt Disease or Fusarium Head Blight. These proteins may be used for hindering such conditions from spreading, or alternatively, as prophylactic measures to diminish the risk of such conditions from occurring. </p><p id="p0091" num="0091">The novel S. mycoparasitica proteins disclosed herein may be used to treat, ameliorate, or otherwise control infections of Fusarium fungi. The proteins may be applied in any suitable manner to the organism in need of treatment. For example, the proteins may be used directly or alternatively, they may be further processed into inoculants for application to soils systems or soil-less growing systems (e.g., granular compositions, peat-based compositions), for application to seeds (e.g., powdered compositions, granular compositions, peat-based compositions, liquid compositions), or application to growing plants (e.g., powdered compositions, liquid-based compositions). </p><p id="p0092" num="0092">The formulations disclosed herein comprise (i) one or more active ingredients comprising one or more of the novel proteins, (ii) one or more carriers - often an inert material used to support and deliver the densely populated active ingredient to the target, and 
<!-- EPO <DP n="12"/>-->
 optionally (iii) one or more adjuvants - compounds that: promote and sustain the function of the active ingredient by protection from UV radiation, that ensure rain fastness on the target, that retain moisture or protect against desiccation, and/or that promote the spread and dispersal of the biopesticide using standard agriculture equipments such as those disclosed by Hynes and Boyetchko (2006, Research initiatives in the art and science of biopesticide formulations. Soil Biol. &amp; Biochem. 38: 845-49). </p><p id="p0093" num="0093">Internal Transcribed Spacer ribosomal DNA from S. mycoparasitica was sequenced. A 560bp DNA sequence from the ITS region is given in SEQ ID NO: 3. </p><p id="p0094" num="0094">SEQ ID NO: 3 </p><p id="p0095" num="0095"> 1 ttcgtttctt atcgcattgg tgaccagcgg agggtcatta cgaatcggac catttatgtc </p><p id="p0096" num="0096"> 61 atggctctgc caaccctgtg aactttatac ttgtacgttg cctcggcgga acctgccttt </p><p id="p0097" num="0097"> 121 tcggcaggcc gccggccggc atatacgcaa acgctctgaa aaagctccgc gctctatctg </p><p id="p0098" num="0098"> 181 aataataaaa ctttaacgag taaaaacttt tggcaacgga tctcttggct ctggcatcga </p><p id="p0099" num="0099"> 241 tgaaaaacgc agcgaaatgc gatacgtaat gtgaattgca gaattcagtg aaccatcgaa </p><p id="p0100" num="0100"> 301 tctttgaacg caccttgcgg ccgccggtaa tccggcggcc atgcccgtcc gagcgtcgtt </p><p id="p0101" num="0101"> 361 tccaccctcg ggagttctcc tcctaagaaa atttctcccg gccttgggcc agcgcgttgc </p><p id="p0102" num="0102"> 421 gcggctgccc gaccaacggc ggcaggaccg gcgatgtcct ctgtgccctg catttatata </p><p id="p0103" num="0103"> 481 aaactcgcat tggtccccgg taaggcttgc cttgcaacca acttctttag gtcgacctca </p><p id="p0104" num="0104"> 541 gatcggatag ggatacccgc </p><p id="p0105" num="0105">Total intracellular protein extracts and extracellular protein extracts from Sphaerodes mycoparasitica demonstrate significant inhibition of the germination of fungal spores of Fusarium spp., Sclerotinia spp., Rhizoctonia spp., and Pithium spp. Four novel proteins having mycocidal effects were isolated from the total protein extracts, one having a molecular weight of about 79 kDa and comprising SEQ ID NO:4, another having a molecular weight of about 50 kDa and comprising SEQ ID NO:5, another having a molecular weight of about 36 kDa and comprising SEQ ID NO:6, and the fourth having a molecular weight of about 13 kDa and comprising SEQ ID NO: 7. The present invention provides an antifungal agent comprising one or more of these proteins. </p><p id="p0106" num="0106">Conventional molecular biological techniques may be used to isolate, characterize and produce each of the four novel proteins. For example, in order to identify the gene(s) for the present proteins, S. mycoparasitica could be challenged with F. oxysporum filtrates and upregulated mRNA isolated by standard Northern Blot. cDNA can be produced from the 
<!-- EPO <DP n="13"/>-->
 mRNA by Reverse Transcriptase PCR (RT-PCR). The cDNA can be amplified, purified and inserted into an appropriate vector. This vector may be inserted into an appropriate host cell. </p><p id="p0107" num="0107">Cloning and expression may focus on isolation of genes coding for these novel antimicrobial proteins by designing primers for the identified proteins. Isolated genes may be cloned in suitable expression vectors (yeast or bacteria) with suitable/efficient promoters in order to generate industrial strains for large-scale production of the concerned proteins. These vectors can be purchased from Promega, Invitrogen, Clontech, or other companies. The cloned genes may be tested for their protein expression, and the expressed proteins will be purified (using His-tag or other columns). The purified proteins may be tested for their antifungal activity against plant-pathogenic fungi using methods exemplified by the disc-plate assay and/or the microtitre plate assay methods disclosed by Drummond et al. (2000, The development of microbiological methods for phytochemical screening. Rec. Res. Dev. Phytochem. 4: 143-152). Then, rDNA technologies, involving gene mutation or addition of enhancers, introns or protein-specific promoters (GA inducible), or addition deletion may be used to enhance the production of proteins. </p><p id="p0108" num="0108">The selected genes encoding for one or more or all of the novel proteins, i.e., the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein, may be transformed into selected plant genomes to create a transgenic lines with antifungal activity against pathogenic fungi using techniques known to those skilled in these arts such as those exemplified by Sanghyun et.al. (2008, Transgenic wheat expressing a barley class II chitinase gene has enhanced resistance against Fusari m graminearum. J. Expt. Botany, 59, 2371-2378) and Tobias et. al. (2007, Co-bombardment, integration and expression of rice chitinase and thaumatin-like protein genes in barley (Hordeum vulgare cv. Conlon). Plant Cell Reports 26: 631-639). Suitable crop plants for transformation with these novel proteins are exemplified by oil seed crops, grain crops, pulse crops, coniferous tree species, and deciduous tree species among others. Exemplary oil seed crops include canola, mustard, rapeseed, soybean, flax, sunflower, safflower, castor bean, and camelina among others. Exemplary grain crops include wheat, barley ,oats, triticale, rye, rice, maize, sorghum, and quinoa, among others. Exemplary pulse crops include beans, peas, chickpeas, lentils, and lupins among others. Exemplary coniferous tree species include, pine, spruce, fir, and hemlock,\ among others. Exemplary deciduous tree species include poplar, aspen, maple, oak, nut-producing trees, fruit trees, acacia, and eucalyptus among others. 
<!-- EPO <DP n="14"/>-->
 The present invention provides antifungal compositions comprising one or more or all of the 79 kDa protein (comprising SEQ ID NO:4), the 50 kDa protein (comprising SEQ ID NO:5), the 36 kDa protein (comprising SEQ ID NO:6), and the 13 kDa protein (comprising SEQ ID NO: 7) produced by S. mycoparasitica. Alternatively, one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein may be produced by transformed microorganisms provided with one or more nucleic acid molecules encoding the one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein. The present invention also provides a method of controlling a fungal disease of a plant, and a method for mycotoxin detoxification, which methods comprise applying to the locus of the plant one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein, collectively hereinafter referred to as the 'antifungal agent'. </p><p id="p0109" num="0109">The compositions of the invention may, for example, be applied to the seeds of plants and/or to growth media (e.g. soil or water) used for growing plants and/or to the roots of plants and/or to the foliage of plants, or to any combination thereof. Exemplary crop plants that can be treated with the present compositions include agricultural crops such as seed crops, grain crops, pulse crops, horticultural crops, forestry crops, and turf grasses. </p><p id="p0110" num="0110">The present invention provides a composition comprising the antifungal agent and one or more of an agriculturally acceptable carrier and/or diluent, which will ensure stability and/or performance of the final product. Suitable carriers are exemplified by clay dusts exemplified kaolinite, bentonite, and montmorinollite, peat granules, peat powders, carbon dust, cellulosic granules and dust exemplified by sawdust, vermiculite, perlite, pomice, methylcellulose, talc, among others. Suitable diluents are exemplified by water and by non- viscous gels exemplified by alginates, carageenans, agars, carboxymethyl cellulose, and the like. The carrier or diluent should be compatible with the active ingredient, agriculturally acceptable, have a good absorptive capacity and have a suitable bulk density, allowing easy particle dispersion and attachment. </p><p id="p0111" num="0111">The compositions herein may be applied, as in aqueous sprays, granules and dust formulations in accordance with established practice in the art. An aqueous spray is usually prepared by mixing a wettable powder or emulsifiable concentrate formulation of a compound of the invention with a relatively large amount of water to form a dispersion. 
<!-- EPO <DP n="15"/>-->
 Wettable powders may comprise a finely divided mixture of the antifungal agent, a solid carrier, and a surface-active agent. The solid carrier is usually chosen from among attapulgite clays, kaolin clays, montmorillonite clays, diatomaceous earths, finely divided silica, purified silicates, or combinations thereof. Surfactants which may be useful herein have wetting, penetrating, and/or dispersing ability. They are typically present in an amount of from about 0.5% to about 10% by weight. Surfactants herein may be chosen from, for example, alkylbenzenesulfonates, alkyl sulfates, naphthalenesulfonates and condensed naphthalenesulfonates, sulfonated lignins, and non-ionic surfactants. </p><p id="p0112" num="0112">Emulsifiable concentrates may comprise the antifungal agent of the invention in a liquid carrier, the carrier being a mixture of a water-immiscible solvent and a surfactant. Solvents that may be useful herein include aromatic hydrocarbon solvents such as the xylenes, alkylnaphthalenes, petroleum distillates, terpene solvents, ether-alcohols, organic ester solvents or suitable combinations thereof. </p><p id="p0113" num="0113">When a composition of the invention is to be applied to plant debris or litter, in order to control the source of contamination and inoculant dispersion, or to the soil, as for pre-emergence protection, granular formulations or dusts are sometimes more convenient than sprays. </p><p id="p0114" num="0114">In one embodiment the antifungal agents disclosed herein are encapsulated into alginate pellets. The pellets may be prepared in any suitable manner. For example, one useful method is described in Harveson et. al. (2002, Novel Use of a Pyrenomycetous Mycoparasite for Management of Fusarium Wilt of Watermelon. Plant Disease 86(9): 1025-1030). </p><p id="p0115" num="0115">The composition may comprise other active substances useful in an antifungal agent. For example, the compositions herein may comprise other antifungal agents such as Trichoderma, sulfur, neem oil, rosemary oil, jojoba oil, Bacillus subtilis, allylamines (e.g. terbinafine, antimetabolites (e.g. flucytosine), azoles (e.g. ketoconazole, itraconazole), echinocandins (e.g. caspofungin), polyenes (e.g. amphotericin B), systemic agents (e.g. griseofluvin), or combinations thereof. </p><p id="p0116" num="0116">The compositions herein may contain from about 0.1% to about 95%, by weight, of the antifungal agent and from about 0.1% to about 95%, by weight, of the carrier and/or surfactant. The direct application to plant seeds prior to planting may be accomplished in 
<!-- EPO <DP n="16"/>-->
 some instances by mixing either a powdered solid compound of the invention, or a dust formulation, with seed to obtain a substantially uniform coating which is very thin and represents only one or two percent by weight or less, based on the weight of the seed. In some instances, however, a non-phytotoxic solvent such as methanol is conveniently employed as a carrier to facilitate the uniform distribution of the compound of the invention on the surface of the seed. </p><p id="p0117" num="0117">The compositions herein may be useful in the treatment of fungal infections in plants. Consequently, the compositions herein may comprise one or more or all of the 79 kDa protein (comprising SEQ ID NO:4), the 50 kDa protein (comprising SEQ ID NO:5), the 36 kDa protein (comprising SEQ ID NO: 6), and the 13 kDa protein (comprising SEQ ID NO: 7) disclosed herein, and acceptable carriers therefor. </p><p id="p0118" num="0118">The present invention relates to an exemplary method for producing an antifungal composition comprising one or more or all of the S. mycoparasitica 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein. The method comprises: </p><p id="p0119" num="0119"> (a) inducing sporulation of S. mycoparasitica spores; </p><p id="p0120" num="0120"> (b) culturing S. mycoparasitica; </p><p id="p0121" num="0121"> (c) recovering proteins from the S. mycoparasitica culture, </p><p id="p0122" num="0122"> (d) separating and recovering one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein from the recovered S. mycoparasitica proteins; and </p><p id="p0123" num="0123"> (e) preparing a composition comprising one or more or all of the recovered 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein from the S. mycoparasitica proteins. </p><p id="p0124" num="0124">The 79 kDa protein (comprising SEQ ID NO:4), the 50 kDa protein (comprising SEQ ID NO:5), the 36 kDa protein (comprising SEQ ID NO:6), and the 13 kDa protein (comprising SEQ ID NO: 7) may be separated and recovered together from the recovered S. mycoparasitica proteins. Alternatively, the 13 kDa protein and/or the 36 kDa protein and/or the 50 kDa protein and/or the 79 kDa protein, or any combination thereof may be recovered individually from the recovered S. mycoparasitica proteins. </p><p id="p0125" num="0125">The present invention relates to another exemplary method for producing an antifungal composition comprising one or more or all of the S. mycoparasitica 79 kDa 
<!-- EPO <DP n="17"/>-->
 protein (comprising SEQ ID NO:4), the 50 kDa protein (comprising SEQ ID NO:5), the 36 kDa protein (comprising SEQ ID NO:6), and the 13 kDa protein (comprising SEQ ID NO:7). The method comprises: </p><p id="p0126" num="0126"> (f) transforming a selected microbial culture with one or more genes encoding for one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein produced by S. mycoparasitica; </p><p id="p0127" num="0127"> (g) culturing the transformed microbial culture; </p><p id="p0128" num="0128"> (h) recovering proteins from the transformed culture, </p><p id="p0129" num="0129"> (i) separating and recovering 13 kDa protein and/or the 36 kDa protein and/or the 50 kDa protein and/or the 79 kDa protein from the recovered proteins; and</p><p id="p0130" num="0130">(j) preparing a composition comprising one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein. </p><p id="p0131" num="0131">The 13 kDa protein and/or the 36 kDa protein and/or the 50 kDa protein and/or the 79 kDa protein may be separated and recovered together from the recovered proteins. Alternatively, 13 kDa protein and/or the 36 kDa protein and/or the 50 kDa protein and/or the 79 kDa protein may be recovered individually from the recovered proteins. Suitable microbial cultures that may be transformed with one or more genes encoding for one or more or all of the 13 kDa protein, the 36 kDa protein, the 50 kDa protein, and the 79 kDa protein produced by S. mycoparasitica are exemplified by bacterial cultures such as Escherichia coli, Pseudomonas spp., Bacillus spp., and the like, yeast cultures such as Zygosaccharomyces spp., Saccharomyces spp., Pichia spp., Kluveromyces spp. and the like, and Penicillium spp. and the like. </p><p id="p0132" num="0132">EXAMPLES </p><p id="p0133" num="0133">Example 1: Production and extraction of intracellular and extracellular proteins from </p><p id="p0134" num="0134"> Sphaerodes mycoparasitica </p><p id="p0135" num="0135"> Sphaerodes mycoparasitica strains IDAC 301008-02 and/or IDAC 301008-03 were used in all of the studies disclosed herein, and are referred throughout as "SM-Bst" and "SMGst" respectively. Stock cultures of SM-Bst and SM-Gst were prepared and maintained in potato dextrose broth (PDB) culture media at 21° C. To prepare intracellular and extracellular proteins from each type of stock culture, about 3 ml were transferred from the PDB culture to 250-ml Erlenmeyer flasks containing 50 ml PDB growth medium. The flasks 
<!-- EPO <DP n="18"/>-->
 were incubated for 7 days on a rotary shaker (150 rpm) at room temperature. Young mycelia were filtered through Whatman<sup>®</sup> No.l filter paper (Whatman is a registered trademark of Whatman International Ltd., Kent, UK). Mycelia collected on the Whatman<sup>®</sup> No. 1 filter paper were used for extraction of intracellular proteins, whereas the filtered culture media was used for recovery of extracellular proteins therefrom. </p><p id="p0136" num="0136">Example 2: Fractionation, separation and purification of intracellular proteins and extracellular proteins from Sphaerodes mycoparasitica </p><p id="p0137" num="0137">Intracellular protein extraction: Intracellular proteins were extracted according to the method disclosed by Chen et al. (2004, Heat shock proteins of thermophilic and thermotolerant fungi from Taiwan. Bot. Bull. Acad. Sin. 45: 247-257). A total of 200 mg of the fungi mycelium from each sample was powdered in liquid nitrogen in a sterile porcelain mortar using a pestle, mixed with 1.5 ml chilled extraction buffers. Mycelia (-200 mg) were ground by sonication in a grinding tube containing 1 mL of buffer consisting of 50 mM Tris- HC1 (pH 8.5); 2% sodium dodecyl sulfate (SDS); 2% β-mercaptoethanol; 1 mM phenylmethylsulfonyl fluoride (PMSF in 95% alcohol). The homogenate was centrifuged at 12,000 rpm at 28°C for 10 min, and the supernatant was collected. Four volumes of cold acetone (-20°C) were added, and the samples were frozen overnight at -20°C. The precipitate (proteins) was stored in acetone, centrifuged at 12000 rpm at 28°C for 5 min, and finally dissolved in 50-100 μΐ of sample buffer (62.5 mM Tris-HCl (pH 6.8); 3% SDS; 10% glycerol; 5% β-mercaptoethanol). The protein samples were transferred to new 1.5 ml eppendorf tubes and stored at -80°C until used for further studies. </p><p id="p0138" num="0138">Extracellular protein extraction: Filtered culture medium was used as as the sources of extracellular proteins and was concentrated by Amicon<sup>®</sup> ultrafiltration centrifuge tube with a 3000-Dalton cut-off membrane (Amicon is a registered trademark of the Millipore Corp., Billerica, MA, USA) by centrifugation at 4000 rpm at 4°C. Total extracellular proteins were tested for antifungal activity against the fungal pathogens, Fusarium oxysporum and Fusarium graminearum using a disc diffusion assay. Antifungal activities of total extracellular proteins were tested under sterile conditions by radial disc plate diffusion assay as described by Roberts and Selitrennikoff (1986, Isolation and partial characterization of two antifungal proteins from barley. Biochim. Biophys. Acta, 880: 161-170) with some modifications. Testing of the total extracellular proteins for antifungal activity toward F. oxysporum and F. graminearum was carried out in petri plates containing potato dextrose 
<!-- EPO <DP n="19"/>-->
 agar. Mycelial plugs from actively growing fungal plates were placed in the center of the petri plates and sterile filter paper discs (5 mm diameter of Whatman<sup>®</sup> filter paper no. 1) were placed on the agar surface at a distance of 0.5 cm away from the rim of the mycelial colony. An aliquot (60 μΐ,) containing 2.5 μg of extracellular protein was added to a disk (test spot is identified in Figs. 1(a) A and l(a)B as "T"). Sterile distilled water and buffer served as controls (control spot is identified in Figs. l(a)A and l(a)B as "C"). The plates were then incubated at room temperature for 4 days and examined for inhibition of mycelial outgrowth. The areas of the mycelial colonies were measured and the inhibition of fungal growth was determined by calculating the percent reduction in area of mycelial colony outgrowth relative to the control. The total extracellular proteins recovered from the SMCD culture inhibited mycelial outgrowth in both F. oxysporum and F. graminearum (Figs. l(a)A and l(a)B). Three days after germination commenced, about 22% inhibition in the hyphal extension of F. oxysporum and 30% inhibition in hyphal extension of F. graminearum were observed (Fib 1(b)). One day later, inhibition of hyphal extension of F. oxysporum increased to about 30%, while inhibition of hyphal extension in F. graminearum increased to about 35% (Fig. lb). </p><p id="p0139" num="0139">Native polyacrylamide gel electrophoresis (native-PAGE)'. Proteins (intracellular and extracellular) were separated by 10 % native polyacrylamide gel electrophoresis (native- PAGE) in a discontinuous buffer system using the method taught by Laemmli (1970, Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 227: 680-685). The stacking gel (3.75 % acrylamide/bis-acrylamide 30:0.8 v/v) had 125 mM Tris-HCL, pH 6.8 as buffer and the separating gel (7.5 % acrylamide/ bis-acrylamide 30:0.8 v/v) had 375 mM Tris-HCl, pH 8.8 as buffer. The gels were run at 120 V overnight at 4°C with a Tris-glycine electrode buffer containing 25 mM Tris and 192 mM glycine, pH 8.3. After electrophoresis, the gel was stained according to silver staining methods (Bio-Rad<sup>®</sup> kit methods). </p><p id="p0140" num="0140">Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE): SDS-PAGE of proteins eluted from native-PAGE and total proteins was performed on 12 % polyacrylamide gel following the method taught by Laemmli (1970). Proteins were analyzed by using 5 % stacking gel (pH 6.8) and 12 % separating acrylamide gel (pH 8.8) in Tris-glycine buffer (pH 8.3) and appropriate markers. Prior to SDS-electrophoresis, the protein was mixed with an equal volume of sample buffer (60 mM Tris-HCl buffer, 4% SDS, pH 6.8) containing 5 % β- mercaptoethanol. A mixture of standard marker proteins obtained from Bio-Rad<sup>®</sup> 
<!-- EPO <DP n="20"/>-->
 Laboratories Canada Ltd. (Montreal, PQ, Canada; Bio-Rad is a registered trademark of Bio- Rad Laboratories Inc., Hercules, CA, USA) was used. All samples were heated for 5 min at 95°C and cooled to room temperature. Proteins were visualized by silver staining method (Bio-Rad<sup>®</sup> kit methods). Protein molecular masses were estimated by comparison with the mobilities of standard molecular mass markers. </p><p id="p0141" num="0141">Fast protein liquid chromatography (FPLC) of extracellular proteins: Proteins were fractionated through Superdex<sup>®</sup> 75 GL 10/30 column (Superdex is a registered trademark of GE Healthcare Bio-Sciences AB Ltd., Uppsala, Sweden) using FPLC AKTA<sup>®</sup> purifier system (AKTA is a registered trademark of GE Healthcare Bio-Sciences AB Ltd., Uppsala, Sweden) according to the manufacturer's instructions. The column was previously equilibrated with sterile water and with 50 raM sodium phosphate buffer, pH 7.0 containing 0.15 M NaCl, followed by protein injection (about 500 L) and elution of proteins with the same buffer with a flow rate of 1.0 ml/min. Proteins were purified through gel filtration using 50 mM sodium phosphate buffer, pH 7.0 containing 0.15 M NaCl. Upon gel filtration on Superdex 75, proteins were resolved into distinct peaks. 0.8-ml fractions were collected and their purities were checked by SDS-PAGE. </p><p id="p0142" num="0142">Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE): SDS-PAGE (12 %) of proteins recovered from FPLC fractions was performed following the method taught by Laemmli (1970). All peaks giving FPLC fractions were pooled and recovered by precipitation in 1 :4 volume of chilled acetone and kept at -20°C overnight. After centrifugation at 12,000 g for 10 min, precipitated proteins (pellets) were dissolved in minimum amount (30 μί) of assay buffer. Proteins were analyzed by SDS-PAGE having 5 % stacking gel (pH 6.8) and 12 % separating acrylamide gel (pH 8.8) in Tris-glycine buffer (pH 8.3) and appropriate markers. Prior to SDS-electrophoresis, the protein was mixed with an equal volume of sample buffer (60 mM Tris-HCl buffer, 4% SDS, pH 6.8) containing 5 % β- mercaptoethanol. A mixture of standard marker proteins (Bio-Rad<sup>®</sup> protein markers, Bio-Rad Laboratories Canada Inc.) was used. All samples were heated for 5 min at 95°C and cooled to room temperature before loading on gel. Proteins were visualized by silver staining method (Bio-Rad<sup>®</sup> Silver staining kit, Bio-Rad Laboratories Canada Inc.). Proteins molecular masses were estimated by comparison with the mobilities of standard molecular mass markers. The molecular masses of the fractionated proteins obtained from FPLC were determined by SDS- 
<!-- EPO <DP n="21"/>-->
 PAGE (12 % and 16%). 5% SDS-PAGE was performed to separate the extracellular proteins comprising the large weight protein bands separated by the native-PAGE process. </p><p id="p0143" num="0143">Native-PAGE electrophoresis of intracellular proteins extracted from SM-Bst and SMGst using 10% native polyacrylamide gels separated two bands of proteins designated as upper bands and lower bands (Fig. 2). Each protein band of native-PAGE was immersed in 500-750 μΐ of sample buffer (62.5 mM Tris-HCl, pH 6.8; 1% PMSF, 1 % EDTA) and left overnight at 4°C. The proteins were recovered by centrifugation at 12,000 g for 10 min. SDS- PAGE separation of the intracellular proteins was done using 12 % gels for determination of the molecular weights of the separated proteins eluted from native-PAGE. The eluted proteins from lower and upper bands of intracellular samples showed presence of two distinct bands of approximately 50 and 79 kDa (Fig. 3). </p><p id="p0144" num="0144">Native-PAGE electrophoresis of extracellular proteins extracted from SM-Bst and SMGst using 10% native polyacrylamide gels separated four bands of proteins designated as ECl, EC2, EC3, and EC4 (Fig. 4). Each protein band of native-PAGE was immersed in 500- 750 μΐ of sample buffer (62.5 mM Tris-HCl, pH 6.8; 1% PMSF, 1 % EDTA) and left overnight at 4°C. The proteins were recovered by centrifugation at 12,000 g for 10 min. SDS- PAGE separation of the extracellular proteins was done using 12 % gels for determination of the molecular weights of the separated proteins eluted from native-PAGE. The eluted proteins from the four bands showed presence of separated and purified proteins having molecular weights of about: (i) 79 kDa (ECl), (ii) 50 kDa (CE2), (iii) 36 kDa (EC3), and 13 kDa (EC4) (Fig. 5). </p><p id="p0145" num="0145">The elution profile of the four bands of extracellular proteins on a Superdex 75 GL 10/30 column by determined by FPLC fast protein liquid chromatography using an AKTA<sup>®</sup> Purifier System is shown in Fig. 5. 
<!-- EPO <DP n="22"/>-->
 Example 3: Inhibition of mycelial outgrowth by Fusarium sp. by purifed intracellular proteins and purified extracellular proteins recovered from S. mycoparasitica cultures </p><p id="p0146" num="0146">Antifungal activities of proteins were tested under sterile conditions by radial disc plate diffusion assay following the method taught by Roberts et al. (1986, Isolation and partial characterization of two antifungal proteins from barley. Biochim. Biophys. Acta, 880: 161-170) with some modifications. The assay of the isolated protein for antifungal activity toward F. oxysporum and F. graminearum was carried out in petri plates containing potato dextrose agar. Mycelial plugs from actively growing fungal plates were placed in the center of the petri plates and sterile filter paper discs (5-mm diameter of Whatman<sup>®</sup> filter paper no. 1) were placed on the agar surface at a distance of 0.5 cm away from the rim of the mycelial colony. Isolated proteins (60 μΐ,) were added to the disc. Sterile distilled water and buffer only without antifungal protein served as a control. The plates were then incubated at room temperature for 3-4 days and then examined for zones of inhibition, if any, around the discs. In this manner, if the protein being tested was an antifungal agent, a crescent-shaped zone of inhibition of fungal growth would have occurred around the disc. The area of the mycelial colony was measured and the inhibition of fungal growth was determined by calculating the % reduction in area of mycelial colony with the controls (water and buffer treated plates). </p><p id="p0147" num="0147">Both the 50 kDa intracellular protein and the 79 kDa intracellular protein inhibited the hyphal extension, i.e., mycelial growth of F. oxysporum (Figs. 7(a) - 7(d)) and F. graminearum (Figs. 8(a) - 8(d)). </p><p id="p0148" num="0148">The 79 kDa protein (ECl), the 50 kDa protein (EC2), and the 36 kDa protein (EC3) inhibited mycelial outgrowth of F. oxysporum (Figs. 9(a) - 9(b)) and F. graminearum (Figs. 10(a) - 10(b)). The 13 kDa protein (EC4) inhibited mycelial outgrowth of F. graminearum (Fig. 11 (a)) and F. oxysporum (Fig. 11(b)). 
<!-- EPO <DP n="23"/>-->
 Example 4: Inhibition of spore germination by Fusarium sp. by purified extracellular proteins recovered from S. mycoparasitica cultures </p><p id="p0149" num="0149">The inhibitory effects on Fusarium sp. spore germination by the four extracellular S. mycoparasitica proteins ECl, EC2, EC3, and EC4 were assessed using the microtitre plate assay method disclosed by Ghosh (2006, Antifungal Properties of Haem Peroxidase from Acorus calamus. Ann. Bot. 98: 1145-1 153) and Yadav et al. (2007, An antifungal protein from Escherichia coli. J. Med. Microbiol. 56: 637-644). The possible toxicity of the fractionated proteins was tested using the fungi F. oxysporum and F. graminearum with a percentage growth inhibition assay. The in vitro antifungal activities of fractionated proteins were determined in 96-well microtiter plates. In microplate wells, 10 μΐ of potato dextrose broth (PDB; Difco Laboratories, Detroit) were mixed with 3 μΐ of spore suspensions of F. oxysporum and F. graminearum. An aliquot of 7 μΐ, of different peak containing proteins fractions were added to suspensions in microtitre plates (12-8 wells). Water and buffer were used as negative controls. The microtiter plate was then incubated at room temperature in dark. Observations were made for inhibition of spore germination in both untreated and treated wells after 24 h using inverted and fluorescent microscopes. The number of germinated and non-germinated spores and percentage of area covered by mycelia in microscope were used to determine the percentage of growth inhibition. </p><p id="p0150" num="0150">All four extracellular proteins significantly inhibited germination of the spores of F. oxysporum and F. graminearum (Figs. 12(a) and 12(b)). Furthermore, all four extracellular proteins established large zones of inhibition of mycelial growth of F. oxysporum and F. graminearum when these organisms were separately plated onto solid media (Fig. 13). Fig.</p><p id="p0151" num="0151">14A(c) is a micrograph showing germination of control F. oxysporum spores, Fig. 14A(a) shows the inhibitory effects of the 50 kDa protein on germination of F. oxysporum spores, and Fig. 14A(b) shows the inhibitory effects of the 13 kDa protein on germination of F. oxysporum spores. Fig. 14B(c) is a micrograph showing germination of control F. graminearum spores, Fig. 14B(a) shows the inhibitory effects of the 50 kDa protein on germination of F. graminearum spores, and Fig. 14(b) shows the inhibitory effects of the 13 kDa protein on germination of F. graminearum spores. 
<!-- EPO <DP n="24"/>-->
 Example 5: Inhibitory effects of crystal-forming ECl and EC3 proteins recovered from S. mycoparasitica cultures </p><p id="p0152" num="0152">The mycotoxic effects of crystal-forming extracellular proteins ECl (79 KDa) and EC3 (36 KDa) were assessed with actively growing F. avenaceum and F. graminearum cultures on PDA. F. avenaceum was grown on PDA agar until the mycelia covered the surface of the plate. One half of the plate was treated with a mixture of ECl and EC3 crystal proteins after which, the plate was incubated in the dark at 23° C for 5 days. Significant mycelial damage was observed on the half of the plate that was treated with the ECl / EC3 protein mixture (Fig 15(B)) compared to the untreated control side of the plate (Fig. 15(a)). Wheat seeds were sown across the surface of a PDA plate. After the seeds had germinated, the plates were inoculated with F. graminearum. One half of the plate was treated with the ECl / EC3 protein mixture, after which, the plate was incubated in the dark at 23° C for 5 days. There was no fungal growth on the half of the plate that received the ECl / EC3 protein mixture (Fig. 16(b)) while fungal mycelia proliferated on the untreated side of the plate (Fig. 16 (a)). Examination of the surfaces of the agar that had received the ECl / EC3 protein mixture, with confocal laser scanning microscopy showed numerous lysed hyphal elements (see arrows in Fig. 16 (c)). </p><p id="p0153" num="0153">F. graminearum was grown on PDA agar until the mycelia covered the surface of the plate. One half of the plate was treated with a mixture of ECl and EC3 crystal proteins after which, the plate was incubated in the dark at 21° C for 5 days. Significant mycelial damage was observed on the half of the plate that was treated with the ECl / EC3 protein mixture (Fig 17 (B)) compared to the untreated control side of the plate (Fig. 17 (a)). Examination of the surfaces of the agar that had received the ECl / EC3 protein mixture, with scanning electron microscopy showed numerous lysed hyphal elements (see arrows in Fig. 18 (a)). Examination of the same surfaces with chemical force microscopy showed numerous broken hyphal elements and apoptotic-lysed cells (see arrows in Fig. 18 (c)). 
<!-- EPO <DP n="25"/>-->
 Example 6: Sequencing and putative identification of purified extracellular proteins recovered from S. mycoparasitica cultures </p><p id="p0154" num="0154">The extracellular protein bands ECl (79 Kda), EC2 (50 Kda), EC3 (36 Kda), and EC4 (13 KDa) were cut from 5%, 12% and 16%» SDS-PAGE gels. The excised protein bands were sent to the McGill University and Genome Quebec Innovation Centre (Rm 704, 740 Dr. Penfield Avenue, Montreal, PQ, Canada) for sequencing and peptide characterization using MALDI-TOF-MS equipment, and putative identification by comparing the peptide sequences to the UniProtKB/Swiss-Prot and NCBI databases. </p><p id="p0155" num="0155">MALDI-TOF-MS analysis enabled separation of the amino acids comprising the ECl protein (Fig. 19). The sequence of amino acids comprising the ECl protein was determined to be: </p><p id="p0156" num="0156">YLPGGGGGRDEPPPR (SEQ ID NO: 4) </p><p id="p0157" num="0157">The mass of ECl was determined to be 78,688 Da (79 kDa), and its identity was predicted to be similar to the RTX protein toxins and related Ca<sub>2+</sub>-binding proteins. MALDI-TOF-MS separation of the EC2 extracellular protein band (Fig. 20) enabled determination of the amino acid sequence comprising the EC2 protein: </p><p id="p0158" num="0158">LHVQFMSSK (SEQ ID NO: 5) </p><p id="p0159" num="0159">The mass of EC2 was determined to be 49,443 Da (50 kDa), and its identity was predicted to be similar to P-l,4-glucase proteins. MALDI-TOF-MS separation of the EC3 extracellular protein band (Fig. 21) enabled determination of the amino acid sequence comprising the EC3 protein: </p><p id="p0160" num="0160">EIAVTELDIAGASSTDYVEVVEACLNQPK (SEQ ID NO: 6)</p><p id="p0161" num="0161">The mass of EC3 was determined to be 35,578 Da (36 kDa), and its identity was predicted to be similar to Xylanase proteins. 
<!-- EPO <DP n="26"/>-->
 MALDI-TOF-MS separation of the EC4 extracellular protein band (Fig. 22) enabled determination of the amino acid sequence comprising the EC3 protein: </p><p id="p0162" num="0162">TTVSYDTGYDD (SEQ ID NO: 7) </p><p id="p0163" num="0163">The mass of EC4 was determined to be 2,563 Da (this is a truncated fragment because the SDS-Page analysis showed its molecular weight to be 13 kDa), and its identity was predicted to be a hypothetical Cerato-platanin toxin. </p><p id="p0164" num="0164">Example 6: Effects of purified extracellular proteins recovered from S. mycoparasitica cultures on mycelial growth and development of Sclerotinia sclerotiorum, Rhizoctonia solani, and Pythium ultimum The mycostatic and mycotoxic effects of purified extracellular proteins ECl (79 KDa) and EC3 (36 KDa) recovered from S. mycoparasitica cultures were assessed with three additional wide-spread plant pathogens that cause significant damage to agricultural crops. The inhibitory effects of a mixture of the ECl + EC3 extracellular S. mycoparasitica proteins (1 :1) on S. sclerotiorum, R. solani, and P. ultimum, were assessed using the microtitre plate assay method disclosed by Ghosh (2006) and Yadav et al. (2007). Mycelia were collected and biomass weighed after 36 h of growth following the method taught by Strom et al. (2005, Co-cultivation of antifungal Lactobacillus plantarum MiLAB 393 and Aspergillus nidulans, evaluation of effects on fungal growth and protein expression. FEMS Microb Let, 246: 1 19— 124). Figs. 23(a), 23(c), and 23(e) are micrographs of control cultures of S. sclerotiorum, R. solani, and P. ultimum, respectively, grown on PDA for 4 days in the dark at 26° C. Figs. 23(b), 23(d), and 23(f) are micrographs of S. sclerotiorum, R. solani, and P. ultimum, respectively, grown on PDA amended with a (1 : 1) mixture of the ECl (79 kDa) and EC3 (36 kDa) exocellular proteins produced by S. mycoparasitica. The exocellular protein mixture caused significant mycelial damage to all three plant pathogen fungal cultures (Figs. 23(b), 23(d), 23(f)). The data in Fig. 24 demonstrate that the exocellular protein mixture caused: (i) about 80% inhibition in growth of S. sclerotiorum compared to the untreated control, (ii) about 85% inhibition in the growth of R. solani compared to the untreated control, and (iii) about 95% inhibition in the growth of P. ultimum compared to the untreated control. These data demonstrate that the S. mycoparasitica extracellular proteins disclosed herein have mycostatic and mycotoxic effects on a broad range of soil and plant-pathogenic fungi. 
<!-- EPO <DP n="27"/>-->
 The studies disclosed herein clearly demonstrate that exocellular proteins derived from S. mycoparasitica, identified as a 79 kDa protein comprising SEQ ID NO:4, a 50 kDa protein comprising SEQ ID NO:5, a 36 kDa protein comprising SEQ ID NO:6, and a 13 kDa protein comprising SEQ ID NO:7, are useful for inhibiting spore germination of various plant pathogenic fungi such as Fusarium spp., Sclerotinia spp., Rhizoctonia spp., and Pithium spp. The studies disclosed herein further demonstrate that contacting mycelia of plant pathogenic fungi with one or more of these exocellular proteins causes cessation of mycelial growth and results in lyses. Accordingly, transforming a plant cell with one or more nucleic acid molecules that encode one or more polypeptides comprising an amino acid sequences that shares at least 80% sequence identity with SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7 will enable the plant cell to produce one or more polypeptide molecules comprising the amino acid sequences having at least 80% sequence identity with the amino acid sequence disclosed in SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, or SEQ ID NO: 7. Accordingly, when such transformed cells are cultured into plants, the plants comprising the cells will express the polypeptides resulting in formation of the exocellular proteins within the cells. During the processes of colonizing the surfaces of such plants and/or infecting the plants, plant pathogenic fungi coming into proximity with the exocellular proteins and/or into contact with the exocellular proteins will be inhibited and or lysed. 
</p></description><claims mxw-id="PCLM44727737" ref-ucid="WO-2012113051-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="28"/>-->CLAIMS: </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A composition for controlling disease symptoms caused by one or more plant pathogenic fungi, the composition comprising a polypeptide molecule that comprises an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, and SEQ ID NO: 7, and a carrier. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. A composition of claim 1, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 4. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. A composition of claim 1, wherein the polypeptide molecule comprises SEQ ID NO: 4. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. A composition of claim 1, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 5. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. A composition of claim 1 , wherein the polypeptide molecule comprises SEQ ID NO: 5. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. A composition of claim 1, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 6. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. A composition of claim 1, wherein the polypeptide molecule comprises SEQ ID NO: 6. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. A composition of claim 1, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 7. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. A composition of claim 1, wherein the polypeptide molecule comprises SEQ ID NO: 7. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. A composition of any one of claims 1-9, wherein the composition is a seed treatment composition. <!-- EPO <DP n="29"/>--> </claim-text></claim><claim id="clm-0011" num="11"><claim-text>11. A composition of any one of claims 1-9, wherein the composition is a plant treatment composition. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. A composition of any one of claims 1-9, wherein the composition is a soil treatment composition. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. A composition of any one of claims 1-12, wherein the plant pathogenic fungus is one of a Fusarium spp., a Sclerotinia spp., a Rhizoctonia spp., or a Pithium spp. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. Use of the composition of any one of claims 1-13, for controlling disease symptoms in plants caused by one of a Fusarium spp., a Sclerotinia spp., a Rhizoctonia spp., or a Pithium spp. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. Use of claim 14, comprising one or more of treating seeds, treating plants, and treating plant growing substrates. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. Use of a microbial cell that expresses a polypeptide molecule comprising an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, and SEQ ID NO: 7, for controlling disease symptoms caused by one or more plant pathogenic fungi </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. Use of claim 16, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 4. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. Use of claim 16, wherein the polypeptide molecule comprises SEQ ID NO: 4. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. Use of claim 16, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 5. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. Use of claim 16, wherein the polypeptide molecule comprises SEQ ID NO: 5. </claim-text></claim><claim id="clm-0021" num="21"><claim-text>21. Use of claim 16, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 6. <!-- EPO <DP n="30"/>--> </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. Use of claim 16, wherein the polypeptide molecule comprises SEQ ID NO: 6. </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. Use of claim 16, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 7. </claim-text></claim><claim id="clm-0024" num="24"><claim-text>24. Use of claim 16, wherein the polypeptide molecule comprises SEQ ID NO: 7. </claim-text></claim><claim id="clm-0025" num="25"><claim-text>25 Use of any one of claims 16-24, wherein the microbial cell is a fungal cell, a yeast cell, or a bacterial cell. </claim-text></claim><claim id="clm-0026" num="26"><claim-text>26. Use of claim 25, wherein the fungal cell is a Sphaerodes mycoparasitica cell or a Penicillium spp. cell. </claim-text></claim><claim id="clm-0027" num="27"><claim-text>27. Use of claim 25, wherein the yeast cell is a Zygosaccharomyces spp. cell, a Saccharomyces spp. cell, a Pichia spp. cell, or a Kluveromyces spp. cell. </claim-text></claim><claim id="clm-0028" num="28"><claim-text>28. Use of claim 25, wherein the bacterial cell is an Escherichia coli cell, a Pseudomonas spp. cell, or a Bacillus spp. cell. </claim-text></claim><claim id="clm-0029" num="29"><claim-text>29. A transformed plant cell expressing a polypeptide molecule comprising an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, and SEQ ID NO: 7, wherein said plant cell is resistant to infection by Fusarium spp. </claim-text></claim><claim id="clm-0030" num="30"><claim-text>30. A transformed plant cell of claim 29, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 4. </claim-text></claim><claim id="clm-0031" num="31"><claim-text>31. A transformed plant cell of claim 29, wherein the polypeptide molecule comprises SEQ ID NO: 4. </claim-text></claim><claim id="clm-0032" num="32"><claim-text>A transformed plant cell of claim 29, wherein the polypeptide molecule comprises acid sequence that shares at least 80% sequence identity with SEQ ID NO: 5. <!-- EPO <DP n="31"/>--> </claim-text></claim><claim id="clm-0033" num="33"><claim-text>33 A transformed plant cell of claim 29, wherein the polypeptide molecule comprises SEQ ID NO: 5. </claim-text></claim><claim id="clm-0034" num="34"><claim-text>34 A transformed plant cell of claim 29, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 6. </claim-text></claim><claim id="clm-0035" num="35"><claim-text>35 A transformed plant cell of claim 29, wherein the polypeptide molecule comprises SEQ ID NO: 6. </claim-text></claim><claim id="clm-0036" num="36"><claim-text>36 A transformed plant cell of claim 29, wherein the polypeptide molecule comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 7. </claim-text></claim><claim id="clm-0037" num="37"><claim-text>37 A transformed plant cell of claim 29, wherein the polypeptide molecule comprises SEQ ID NO: 7. </claim-text></claim><claim id="clm-0038" num="38"><claim-text>38 A transformed plant cell of any one of claims 29-37, wherein the plant cell is an oil seed plant cell or a grain plant cell or a pulse plant cell. </claim-text></claim><claim id="clm-0039" num="39"><claim-text>39 An isolated protein for controlling disease symptoms caused by one or more plant pathogenic fungi, the isolated protein comprising a polypeptide molecule comprising an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 6, and SEQ ID NO: 7. </claim-text></claim><claim id="clm-0040" num="40"><claim-text>40. An isolated protein of claim 39, wherein the polypeptide sequence comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 4. </claim-text></claim><claim id="clm-0041" num="41"><claim-text>41. An isolated protein of claim 39, wherein the protein comprises SEQ ID NO: 4. </claim-text></claim><claim id="clm-0042" num="42"><claim-text>42. An isolated protein of claim 39, wherein the protein comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 5. </claim-text></claim><claim id="clm-0043" num="43"><claim-text>43. An isolated protein of claim 39, wherein the protein comprises SEQ ID NO: 5. </claim-text></claim><claim id="clm-0044" num="44"><claim-text>44. An isolated protein of claim 39, wherein the protein comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 6. <!-- EPO <DP n="32"/>--> </claim-text></claim><claim id="clm-0045" num="45"><claim-text>45. An isolated protein of claim 39, wherein the protein comprises SEQ ID NO: 6. </claim-text></claim><claim id="clm-0046" num="46"><claim-text>46. An isolated protein of claim 39, wherein the protein comprises an amino acid sequence that shares at least 80% sequence identity with SEQ ID NO: 7. </claim-text></claim><claim id="clm-0047" num="47"><claim-text>47. An isolated protein of claim 39, wherein the protein comprises SEQ ID NO: 7. </claim-text></claim><claim id="clm-0048" num="48"><claim-text>48. An isolated nucleic acid molecule encoding the protein of any one of claims 39-47. </claim-text></claim><claim id="clm-0049" num="49"><claim-text>49. A microbial cell transformed with the nucleic acid molecule of claim 48. </claim-text></claim><claim id="clm-0050" num="50"><claim-text>50. A microbial cell of claim 49, wherein the nucleic acid molecule is operably linked to a promoter. </claim-text></claim><claim id="clm-0051" num="51"><claim-text>51. A microbial cell of claim 49 or 50, wherein the microbial cell is a fungal cell, a yeast cell, or a bacterial cell. </claim-text></claim><claim id="clm-0052" num="52"><claim-text>52. A microbial cell of claim 51, wherein the fungal cell is a Sphaerodes mycoparasitica cell or a Penicillium spp. cell. </claim-text></claim><claim id="clm-0053" num="53"><claim-text>53. A microbial cell of claim 51, wherein the yeast cell is a Zygosaccharomyces spp. cell, a Saccharomyces spp. cell, a Pichia spp. cell, or a Kl veromyces spp. cell. </claim-text></claim><claim id="clm-0054" num="54"><claim-text>54. A microbial cell of claim 51, wherein the bacterial cell is an Escherichia coli cell, a Pseudomonas spp. cell, or a Bacillus spp. cell. </claim-text></claim><claim id="clm-0055" num="55"><claim-text>55. A plant cell transformed with the nucleic acid molecule of claim 48. </claim-text></claim><claim id="clm-0056" num="56"><claim-text>56. A plant cell of claim 55, wherein the nucleic acid molecule is operably linked to a promoter. </claim-text></claim><claim id="clm-0057" num="57"><claim-text>57. A plant cell of claims 55 or 56, wherein the plant cell is an oil seed plant cell, a grain plant cell, or a pulse plant cell. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
